State Street SPDR S&P Biotech ETF
State Street Corp. XBI ETF
| XBI Price | $122.09 |
Market Cap | $8.13B |
| Annual Dividend Yield | 0.37% |
Annual Dividend | $0.45 |
| Yearly Management Fee | 0.35% |
Asset Class | Equity |
| Focus | Health care |
Category | Sector, Health Care |
| Niche | Biotechnology |
Last 24h Volume | $7.2M |
| Portfolio Management Company | State Street Corp. |
Discount/Premium to NAV | -0.02% |
| Inception Date | Jan 31, 2006 |
Market Cap Rank | 258 |
| Monthly AUM Growth | 3.34% |
Holdings Region | North America |
| Management Style | Passive |
Leverage | Non-Leveraged |
| Description | Best investment Environment | Expected Return |
Invests in biotechnology sector stocks. This fund includes companies in the biotechnology field. |
Strong R&D in biotechnology sector, positive clinical trials, and investor interest in the sector |
High return potential, high risk. |
State Street SPDR S&P Biotech ETF is an ETF issued by State Street Corp. on Jan 31 2006.
The main focus of this ETF, which is in the "Equity" asset class, is determined as "Health care".
As of today, the price of XBI ETF according to its net asset value is discounted at -0.02%.
While the total value of the fund shows $262.94M increase compared to the previous month, its price is traded daily at a increase of 1.61%.
The annual dividend yield of XBI ETF is 0.37%, whereas its main asset area is North America.
XBI ETF, whose 24-hour total volume is $7.2M, has experienced a $388.02M cash inflow in the last month.
In addition, State Street SPDR S&P Biotech ETF's one-year net asset value total return is 30.46%.
XBI ETF Returns
| Daily |
Weekly |
Monthly |
3 Mo |
6 Mo |
YTD |
Yearly |
| 1.61% |
-0.85% |
-1.36% |
17.06% |
38.94% |
-0.15% |
31.85% |
XBI ETF NAV Total Return
| Monthly |
3 Mo |
YTD |
Yearly |
3 Years |
5 Years |
| -2.29% |
16.40% |
-1.47% |
30.46% |
45.19% |
-14.17% |
XBI ETF Comments
no comments yet